AMRZ
Amrize AG
$53.33
▼ 0.6%Updated Today 12:11 PM ET
AMRZ at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 48/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 6.9% over the last 12 months
Market Cap
$29.65B
P/E
25.65x
Forward P/E (est.)
—
ROE
8.9%
Revenue Growth
—
EPS Growth
—
Profit Margin
9.7%
FCF Yield
—
Debt / Equity
0.43x
ROIC
8.0%
Interest Coverage
—
Current Ratio
1.4x
Dividend Yield
—
Implied Growth (rev. DCF)
4.0%
Rating Score
48/100
Amrize AG (AMRZ) is a large-cap company in the Construction industry, part of the Industrials sector of the S&P 500, with a market value around $29.65B.
In its latest reported year it generated about $11.81B in revenue and $1.19B in net profit.
Our model rates AMRZ Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what AMRZ's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. AMRZ trades near $53.33, around its 50-day average ($53.25) and 200-day average ($53.89). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. AMRZ's is $1.99 (~3.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month AMRZ found buyers near $50.41 (support) and sellers near $56.99 (resistance); its 52-week range is $44.12–$65.94. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.2× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
2Y CAGR
0.6%
Revenue moved from $11.68B in 2023 to $11.81B in 2025, a 0.6% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
25.7%
Operating Margin
16.1%
Net Margin
10.0%
ROE
8.9%
Amrize AG keeps about 9.7% of each sales dollar as net profit, with a 25.7% gross margin and 16.1% operating margin. Return on equity is 8.9% and return on invested capital about 8.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$5.27B
Net Debt
$4.17B
Net Debt / EBITDA
2.19x
Debt / Equity
0.43x
Leverage: debt-to-equity is 0.4x, with a current ratio of 1.4x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $5.27B of total debt against $1.10B of cash.
Operating CF
$2.21B
Free Cash Flow
$1.42B
FCF Margin
12.0%
In the latest year Amrize AG produced about $2.21B of operating cash flow and $1.42B of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
25.65x
P/S
2.51x
P/B
—
EV / EBITDA
12.57x
AMRZ trades at 25.6x trailing earnings, 2.5x sales. Reverse-engineering today's price implies the market expects roughly 4.0% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$44.04
Current price
$53.33
Starting FCF (latest 10-K)
$1.42B
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where AMRZ sits versus its Industrials sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 87 Industrials companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How AMRZ stacks up against its Industrials peers — valuation, profitability, and growth versus the sector median.
In the Industrials sector (165 S&P 500 companies), AMRZ ranks #47 of 165 by our overall rating. It trades at a discount versus the sector on earnings (25.6x P/E vs. 32x median) with a lower return on equity (8.9% vs. 19.7%).
P/E vs sector
25.6x
median 32x
ROE vs sector
8.9%
median 19.7%
Growth vs sector
—
median 5.2%
Sector rank
#47
of 165 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Industrials companies by sub-industry and size. Sector median is across all 165 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $53.33 today · expected CAGR -1% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $12.76B | $13.78B | $14.88B | $16.07B | $17.36B |
| Net income | $1.28B | $1.38B | $1.49B | $1.61B | $1.74B |
| EPS | $2.31 | $2.49 | $2.69 | $2.90 | $3.14 |
| Share price (low) | $36.88 | $39.83 | $43.02 | $46.46 | $50.18 |
| Share price (high) | $59.94 | $64.73 | $69.91 | $75.50 | $81.54 |
| CAGR (low–high) | -31% / 12% | -14% / 10% | -7% / 9% | -3% / 9% | -1% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for AMRZ:
- A conservative balance sheet (debt/equity 0.4x) lowers risk.
- As an established S&P 500 member in Industrials, it brings scale and a long operating history.
The case against AMRZ:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Amrize AG is a large-cap industrials business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 25.6x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
AMRZ — frequently asked questions
Is AMRZ a good stock to buy?
We don't give buy or sell advice. Our model rates Amrize AG Neutral (48/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is AMRZ's rating on The Stocks School?
Amrize AG currently scores 48/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does AMRZ's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Amrize AG's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for AMRZ calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this AMRZ analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell AMRZ. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.